Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999920 · ClinicalTrials.gov registry record · Phase 4
Vilazodone for Separation Anxiety Disorder
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT01999920 is a Phase 4 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 24 participants.
The verdict
NCT01999920, a Phase 4 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Vilazodone (Viibryd), an SSRI and 5HT1a receptor agonist, is effective in treating Adult Separation Anxiety Disorder over a 12-week treatment course.
Interventions
- DRUG Placebo
- DRUG Vilazodone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-12 |
| Est. Completion | 2017-12-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01999920
The ClinicalTrials.gov registry entry for NCT01999920 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01999920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01999920 about?
NCT01999920 is a clinical study titled "Vilazodone for Separation Anxiety Disorder". The purpose of this study is to determine whether Vilazodone (Viibryd), an SSRI and 5HT1a receptor agonist, is effective in treating Adult Separation Anxiety Disorder over a 12-week treatment course.
What is the current status of trial NCT01999920?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2013-12. Estimated completion is 2017-12-30.
What interventions are being tested in trial NCT01999920?
The interventions under investigation include: Placebo (DRUG), Vilazodone (DRUG).
Who is sponsoring clinical trial NCT01999920?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.